Beta blockers: the extended family
- PMID: 6152107
Beta blockers: the extended family
Abstract
Beta-Adrenergic blocking drugs, by occupying beta receptors without stimulating adenylate cyclase, interfere with the physiologic responses mediated by the sympathetic nervous system. This property has led to their application in the cardiovascular disorders on which sympathetic tone either underlies or contributes to the pathogenesis of the process. Lipid solubility, selective beta-receptor blockade, and intrinsic sympathomimetic activity are three additional characteristics of beta blockers that modify the pharmacodynamics and pharmacologic effects of each agent. As the role of the sympathetic nervous system in the pathogenesis of heart disease is better defined, the development of beta blockers with particular pharmacologic profiles and fewer side effects may provide more specific treatment.
Similar articles
-
[Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].Herz. 1982 Jun;7(3):168-78. Herz. 1982. PMID: 6124492 German.
-
Differences in betablocking drugs in cardiovascular therapy.Ann Clin Res. 1988;20(5):324-33. Ann Clin Res. 1988. PMID: 2905877
-
[Therapeutic indications for sotalol 160 mg].Ann Cardiol Angeiol (Paris). 1985 Jan;34(1):45-52. Ann Cardiol Angeiol (Paris). 1985. PMID: 2579609 French. No abstract available.
-
[Beta-adrenergic receptor blockers in clinical practice].Orv Hetil. 2004 Sep 19;145(38):1951-60. Orv Hetil. 2004. PMID: 15535106 Review. Hungarian.
-
Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.Clin Pharm. 1986 Apr;5(4):288-303. Clin Pharm. 1986. PMID: 2871961 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials